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A B S T R A C T
Converging clinical and preclinical evidence has shown that dysfunction of the glutamate system is a core feature
of major depressive disorder. In this context, the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has
raised growing interest as fast acting antidepressant.
Using the chronic mild stress (CMS) rat model of depression, performed in male rats, we aimed at analyzing
whether hippocampal specific changes in subunit expression and regulation of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) or NMDA ionotropic receptors and in metabotropic glutamate receptors could
be associated with behavioral vulnerability/resilience to CMS. We also assessed whether acute ketamine (10 mg/
kg) was able to dampen the alterations in CMS vulnerable animals.
Although chronic stress and ketamine had no effect on ionotropic glutamate receptors mRNAs (expression,
RNA editing and splicing), we found selective modulations in their protein expression, phosphorylation and
localization at synaptic membranes. AMPA GluA2 expression at synaptic membranes was significantly increased
only in CMS resilient rats (although a trend was found also in vulnerable animals), while its phosphorylation at
Ser880 was higher in both CMS resilient and vulnerable rats, a change partially dampened by ketamine. In the
hippocampus from all stressed groups, despite NMDA receptor expression levels were reduced in total extract,
the levels of GluN2B-containing NMDA receptors were remarkably increased in synaptic membranes. Finally,
mGlu2 underwent a selective downregulation in stress vulnerable animals, which was completely restored by
acute ketamine.
Overall, these results are in line with a hypofunction of activity-dependent glutamatergic synaptic trans-
mission induced by chronic stress exposure in all the animals, as suggested by the alterations of ionotropic
glutamate receptors expression and localization at synaptic level. At the same time, the selective modulation of
mGlu2 receptor, confirms its previously hypothesized functional role in regulating stress vulnerability and, for
the first time here, suggests a mGlu2 involvement in the fast antidepressant effect of ketamine.
1. Introduction
The stress response is a physiological event, including biological and
psychological processes activated in response to internal or external
challenges or “stressors”, that lead to the alteration of physiological
homeostasis (Joels and Baram, 2009; Popoli et al., 2011; McEwen,
2013). The stress response is aimed at reaching a new equilibrium
through adaptation, the so called “allostasis”, allowing to activate
coping strategies for survival. However, physical or psychological
stress, especially when repeated, particularly intense, and affecting
genetically susceptible subjects, is also recognized as main risk and
precipitating factor for a number of systemic and neuropsychiatric
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disorders, including Major Depressive Disorder (MDD) (McEwen,
2017). Indeed, although everybody is exposed to stress throughout life,
a high majority of people display resilience to stress and cope with it,
while less than 20% of the individuals develop stress-related disorders
(Del Giudice et al., 2011; Han and Nestler, 2017). In this context, one of
the main issues in the study of the pathophysiology of stress-related
disorders is the identification of molecular underpinnings of resilience
and vulnerability to stress (Ozbay et al., 2008; Musazzi et al., 2017a).
Dysfunction of the glutamate system has been consistently shown to
have a primary role in stress-related disorders and MDD (Sanacora
et al., 2012; Duman et al., 2019). Neuroimaging studies have reported
volumetric, functional, and connectivity alterations in cortico-limbic
areas, including hippocampus (HPC), prefrontal cortex, and amygdala,
where glutamatergic transmission predominates. On the other hand,
preclinical evidence from stress-based animal models of depression has
shown atrophy/remodeling of dendrites in the same brain regions af-
fected in humans, suggesting that stress-induced maladaptive changes
have a primary role in the chain of events precipitating or exacerbating
MDD (Liu and Aghajanian, 2008; Popoli et al., 2011; McEwen et al.,
2015; McEwen et al., 2016).
Many studies reported that both acute and chronic stress paradigms
induce molecular and functional changes of ionotropic glutamate re-
ceptors (Yuen et al., 2009; Calabrese et al., 2012; Yuen et al., 2012;
Kallarackal et al., 2013; Bonini et al., 2016). However, in our knowl-
edge, no previous reports have explored a possible involvement of io-
notropic glutamate receptors expression and localization in stress vul-
nerability, by assessing differences of glutamate receptors between
stress-resilient and vulnerable animals. At the same time, changes in
glutamate receptors RNA editing and splicing, which play a key role in
regulating receptor localization and functional properties (Filippini
et al., 2017), were never assessed in the context of chronic stress vul-
nerability/resilience.
Glutamate metabotropic receptors (mGlu) have also been involved
in the regulation of the stress response (Peterlik et al., 2016). In par-
ticular, although conflicting results were obtained from different groups
using different animal models of stress, mGlu2 levels were reported to
be linked with stress vulnerability (Nasca et al., 2015; Highland et al.,
2019), and antidepressant treatments were found to modulate mGlu2
expression (Morley-Fletcher et al., 2011; Bigio et al., 2016; Nasca et al.,
2017; Zanos et al., 2019). Both positive and negative allosteric mGlu2
modulators are under development as putative new antidepressant
drugs (O'Brien et al., 2018).
Recent studies reported that a single infusion of sub-anesthetic dose
of ketamine, a non-competitive NMDA receptor antagonist, induces
rapid and sustained antidepressant effect in treatment-resistant patients
(Kraus et al., 2017; Lener et al., 2017; Kraus et al., 2019). In preclinical
studies, ketamine was shown to rapidly reverse the dendritic retraction
and spine loss induced by chronic stress in pyramidal neurons of pre-
frontal cortex and HPC (Anggono and Huganir, 2012; Moda-Sava et al.,
2019; Tornese et al., 2019). It has also been demonstrated that the fast
behavioral and synaptic actions of ketamine require enhancing α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) relative
to N-methyl-D-aspartate (NMDA) receptor currents (Zanos et al., 2016;
Kadriu et al., 2019). Finally, we have recently reported that both basal
and depolarization-evoked presynaptic exocytotic glutamate release
were significantly reduced in the HPC of Chronic Mild Stress (CMS)
vulnerable rats, compared to controls and resilient animals (Tornese
et al., 2019). Acute ketamine completely rescued basal glutamate re-
lease (a key regulator of homeostatic plasticity), but not depolarization-
evoked release, in just 24 h.
With this study, we aimed at identifying specific changes of AMPA,
NMDA and mGlu receptor subunit expression and AMPA RNA editing
and splicing, in the HPC of rats phenotypically resilient or vulnerable to
the effects of CMS. We also assessed whether acute ketamine was able
to dampen the alterations in CMS vulnerable animals.
2. Material and methods
2.1. Animals
Experiments were performed in accordance with the European
Community Council Directive 2010/63/UE and approved by the Italian
legislation on animal experimentation (Decreto Legislativo 26/2014,
authorization N 308/2015-PR). A total of 47 male Sprague-Dawley 150-
175 g rats (Charles River, Calco, Italy) were housed two per cage at
20–22 °C, 12 h light/dark cycle (light on 7:00 a.m. off 7:00 p.m.), water
and food ad libitum, except when required for CMS (Tornese et al.,
2019).
2.2. Sucrose preference test
Sucrose preference test was performed as previously reported
(Strekalova et al., 2011; Tornese et al., 2019). Two days before the start
of CMS, sucrose habituation was performed exposing animals to two
bottles containing 1% sucrose solution, for 2 h. Animals were subjected
to sucrose preference test one day before the start of CMS (to assess
baseline preference), after 3 and 5 weeks (1 h before sacrifice). Sucrose
preference test consisted in presenting rats with two bottles, one con-
taining 0.5% sucrose and one containing tap water, for 1 h. The position
of the bottles was inverted after 30 min. The animals were not food
and/or water deprived before the test, but only food deprived during
sucrose exposure. Sucrose preference was calculated as: [sucrose solu-
tion intake (ml)/total fluid intake (ml)]x100]. After 3 weeks of CMS,
sucrose preference test was used to divide stressed animals in CMS re-
silient (CMS-R) and vulnerable (CMS-V), applying a cut-off of pre-
ference at 55% (Tornese et al., 2019).
2.3. Chronic mild stress
Rats were randomly divided in two experimental groups: control
(CNT; non-stressed: n = 12) and CMS (stressed: n = 35) groups. CMS
rats were subjected to mild, unavoidable and unpredictable stressors,
including food/water deprivation (8–12 h), crowding (rats were ran-
domly housed five per cage for 6–12 h), isolation (each rat was in-
dividually housed for 6–12 h), soiled cage (rats were housed in cages
soiled with 500 ml of water in the sawdust for 6–12 h), cage tilting
(cages were tilted 45° left or right for 6–12 h), light-on overnight, light/
dark reversal and forced swim (rats were forced to swim in 40 cm of
room temperature water in a 30 cm in diameter Plexiglas cylinder, for
5 min once a week), for a total of 5 weeks (Willner, 2017; Tornese et al.,
2019). Different stressors did not follow a predetermined order and
were randomly performed along the five weeks of CMS, except for
forced swim, which was never assigned before or after food/water de-
privation and generally performed after soiled cage stress. Animals
were subjected to stress at different time of the day and with a different
length of time, in order to minimize prediction (Willner, 2017; Tornese
et al., 2019).
CNT rats were left undisturbed, except for sucrose preference test,
and kept in their home cages.
2.4. Drug treatment
After 4 weeks and 6 days of CMS, CMS-V rats were randomly di-
vided into two groups: one was i.p. injected with a single sub-anesthetic
dose of 10 mg/kg racemic ketamine (MSD Animal Health, Milan, Italy),
while the other received physiological solution (0.9% NaCl). CNT and
CMS-R rats were also injected with physiological solution (Tornese
et al., 2019). All the animals were subjected to sucrose preference test
23 h after treatment and sacrificed immediately after (after 5 weeks of
CMS start and 24 h after treatment).
The HPC was immediately dissected on ice. Up to 10 animals/ex-
perimental group were randomly selected for further molecular studies.
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Left/right hippocampi were separated and randomly assigned to RNA
extraction or homogenization and preparation of synaptic membranes.
2.5. Corticosterone serum levels and adrenal glands weighing
Serum corticosterone levels were measured as in (Musazzi et al.,
2017b). Adrenal glands/total body weight ratio was calculated as: total
weight of left and right adrenal glands (mg)/body weight (g) (Ieraci
et al., 2016).
2.6. RNA isolation and retro-transcription reaction
Dissected HPC was immediately frozen in ethanol/dry ice bath and
kept at−80 °C until RNA extraction. 100 mg of frozen HPC were added
with 1 ml of Tri-Reagent (Sigma-Aldrich, Milan, Italy), and homo-
genized with steel beads in a TissueLyser LT (Qiagen, Milan, Italy) at
50 Hz for 3′. Homogenized tissue was centrifuged in a 5415R Micro-
Centrifuge at 12,000g for 10′ at 4 °C, 200 μl chloroform were added to
the RNA-containing supernatant and total RNA was extracted using
Direct-zol RNA MiniPrep (Zymo Research, Freiburg, Germany), ac-
cording to manufacturer instructions (Bonini et al., 2016; Ieraci et al.,
2016). The concentration of the eluted RNA was measured on a Na-
noVue Plus Spectrophotometer (GE Healthcare Europe GmbH, Milano,
Italy).
Reverse transcription was carried out using Moloney Murine
Leukemia Virus-Reverse Transcriptase (MMLV-RT) (Thermo Fisher
Scientific) for RNA editing and splicing analysis and iScript cDNA
Reverse Transcription kit (BioRad Laboratories, Segrate, Italy) for real-
time PCR experiments following manufactory instructions.
2.7. Quantitative real-time PCR and RNA editing and splicing
quantification
qPCR was performed with Applied Biosystems 7500 or 7900HT Fast
PCR Systems (Applied Biosystems, Monza, Italy), and TaqMan
Universal PCR Master Mix (Applied Biosystems) or iTaq Universal SYBR
Green supermix (BioRad Laboratories), as previously described (Russo
et al., 2013; Tornese et al., 2019). TaqMan Gene Expression Assay id
probes: GRIA1: Rn00709588_m1; GRIA2: Rn00568514_m1; GRIN1:
RN01436038_m1; GRIN2A: Rn00561341_m1; GRIN2B:
Rn00561352_m1 (Applied Biosystems); custom primers for SYBR
Green: GRM2 fwd: TTCCCTCCTCAGTCTTCCACT, rev: TAGTTGACACC
TTTTCGGCCT. The expression ratio of target genes in treated sample
groups, compared to control group, was calculated using the ΔΔCt
method. H2AFZ, GAPDH and PolII geometric mean was used as re-
ference for TaqMan (ID H2AFZ Taqman probe: Rn00821133_g1; ID
GAPDH: Rn99999916_m1; ID PolII: Rn00580118_m1), while the geo-
metric mean of PO and SD18 was used for SYBR Green (PO fwd primer:
AGTCGGAGGAATCCGATGAG, rev primer: ATTAAGCAGGCTGACTTG
GTG; SD18 fwd primer: CATGCAGAACCCACGACAAT, rev primer:
CTTCCCATCCTTCACGTCCT). Each individual determination was re-
peated in triplicate (Russo et al., 2013; Tornese et al., 2019).
The quantification for AMPA receptor subunits GRIA2 Q/R and
GRIA2, GRIA3 and GRIA4 R/G editing levels was measured by sequence
analysis as previously described (Izzi et al., 2002; Orlandi et al., 2011;
La Via et al., 2013; Bonini et al., 2015, 2016).
Briefly, in the electropherogram obtained after RT-PCR and se-
quencing analysis of a pool of transcripts that might be edited or not,
the nucleotide that undergoes the editing reaction appears as 2 over-
lapping peaks: A from unedited transcripts, and G from the edited ones.
The editing level can be reliably calculated as a function of the ratio
between the G peak area and A plus G peaks areas. The areas re-
presenting the amount of each nucleotide were quantified using
Discovery Studio (DS) Gene 1.5 (Accelrys Inc., San Diego, CA, USA),
and the means and standard errors for each experimental group were
calculated and used for subsequent statistical analysis.
The levels of the flip/flop splicing variants were evaluated by se-
quence analysis as described previously (Barbon et al., 2010). For each
of the AMPA receptor subunits, both isoforms were amplified using a
pair of common primers. The amplification products, consisting of both
flip and flop isoforms at different concentrations were sequenced; the
flip and flop exons appeared as peaks superimposed in the electro-
pherogram. Flip and flop exons exhibit mismatches of A/G in specific
locations. The relative expression level of the flip exon can thus be
reliably calculated as the ratio of the peak area of G (flip) and the sum
of the peak areas A + G in different positions. The areas representing
the amount of each nucleotide were quantified using DS-Gene 1.5
(Accelrys Inc., San Diego, CA, USA), and the means and standard errors
for each experimental group were calculated and used for subsequent
statistical analysis.
2.8. Preparation of homogenates and purified synaptic membranes
HPC were homogenized in 0.32 M ice-cold sucrose containing TRIS
0.01 M, 0.1 mM EGTA, 2 ul/ml protease inhibitors (Sigma-Aldrich),
phosphatase inhibitor cocktail (Thermo FisherScientific, Milan, Italy),
pH 7.4. 200 μl of homogenate were aliquoted and immediately frozen.
Purified synaptic terminals (synaptosomes) were freshly obtained
by centrifugation on discontinuous Percoll gradients as previously re-
ported (Treccani et al., 2014). For the preparation of synaptic mem-
branes, synaptosomes were resuspended in lysis buffer: 120 mM NaCl,
20 mM HEPES pH 7.4, 0.1 mM EGTA, 0.1 mM DTT, containing 2 ul/ml
protease inhibitors (Sigma-Aldrich) and phosphatase inhibitor cocktail
(Thermo FisherScientific), pH 7.4. The synaptic membrane fraction was
obtained by centrifugation at 29,000 g for 30′ at 4 °C as described
previously (Musazzi et al., 2010) and stored at −80 °C.
2.9. Western blotting
The BCA protein concentration assay (Sigma–Aldrich, St. Louis, MO,
USA) was used for protein quantitation. Western blotting analysis was
carried out as previously described by incubating PVDF or ni-
trocellulose membranes (GE Healthcare Europe GmbH), containing
electrophoresed and blotted proteins from either homogenates or pre-
synaptic membranes (Bonini et al., 2016; Musazzi et al., 2017b), with
antibodies for total GluA1 (1:200, cod. AGC004, Alomone Labs, Ger-
usalem, Israel), phosphoSer831-GluA1 (1:1000, cod. Ab109464,
Abcam, Milano, Italy), phosphoSer845-GluA1 (1:1000, cod. ab3901
Abcam), GluA2 (1:2500, cod. AGC005, Alomone), phosphoSer880-
GluA2 (1:1.000, cod. Ab52180, Abcam), GluN1 (1:500, cod. AB9864,
Merck Millipore, Milano, Italy), GluN2A (1:500, AB1555P, Merck Mil-
lipore), GluN2B (1:500, cod. 454,582, Calbiochem-Merck Millipore),
mGlu1 (1:1000, cod. Ab82211, Abcam), mGlu2 (1:1000, cod.
Ab106811, Abcam), mGlu5 (1:1000, cod. Ab76316, Abcam). Mouse
monoclonal anti-GAPDH (1:40.000, cod. Mab374, Millipore) or rabbit
monoclonal anti-β-Actin (1:3000, cod.04–1116, Millipore) were used as
internal controls.
Luminescence or chemiluminescence were used for signal detection.
Membranes incubated with secondary horseradish peroxidase-con-
jugated antibodies were detected with a chemiluminescent solution:
ECL Star Enhanced (Euroclone, Milano, Italy) or Clarity (Bio-Rad
Laboratories). For detection of luminescent signal, the membranes were
incubated for 1 h at RT with anti-rabbit secondary antibody (IR-Dye, LI-
COR Biosciences, Lincoln, NE, USA cod: 926–32,211) or anti-mouse
secondary antibody (IR-Dye cod:926–68,020), both diluted 1:2000 in
TBS-T. Signals were detected using an Odyssey infrared imaging system
(LI-COR Biosciences) and quantified using Odyssey version 1.1 (LI-COR
Biosciences).
QuantityOne analysis software (Bio-Rad Laboratories), Image-Pro
Plus and Image Studio software (LI-COR Biosciences) were used for
quantification (Bonini et al., 2016; Musazzi et al., 2017b).
Data are presented as optical density ratios of the investigated
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protein band normalized on GAPDH or β-Actin bands in the same line
and are expressed as percentage of controls. The levels of GluA phos-
phorylated subunits were normalized to respective total GluA levels
(Bonini et al., 2016).
2.10. Data analysis
All the analyses were carried out in individual animals (independent
determinations).
For sucrose preference test on CNT and CMS rats 3 weeks after CMS
start, unpaired two-tailed Student t-test was used. For all the other
experiments, One-Way ANOVA followed by Tukey's post-hoc test was
used. ANOVA F and p values are reported in “Results” section, while the
p values of post-hoc tests are reported in figure legends. NMDA, AMPA
and mGluR receptor subunits were analyzed in independent experi-
ments and no multiple correction was performed. Phosphorylation le-
vels were normalized on total subunit expression.
Data were expressed as means± standard error of the mean (SEM).
Statistical analysis was carried out using GraphPad Prism 8 (GraphPad
Software, La Jolla, CA, USA).
3. Results
3.1. Ketamine reversed anhedonic behavior but did not reduce the levels of
corticosterone in vulnerable animals
Sucrose preference test was applied to assess the anhedonic phe-
notype of all the animals (Tornese et al., 2019). The test was applied
before the start of CMS (to verify that all the animals showed preference
for sucrose: mean 72.11% ± 1.77), then after 3 weeks (to separate the
animals in stress-resilient and vulnerable), and just before sacrifice
(after 5 weeks of CMS, 24 h after 10 mg/kg ketamine injection) (see
methods for more details).
After 3 weeks of CMS, sucrose preference was significantly reduced
in stressed animals (Fig. 1A; unpaired t-test, t = 3.454, p < .01),
however, applying a cut-off at 55% of sucrose preference, rats were
deemed resilient to CMS (CMS-R) (preference for sucrose higher than
55%), or vulnerable (CMS-V) (preference lower than 55%) (Fig. 1B;
One-Way ANOVA, F(2,47) = 38,93 p < .001). After 5 weeks of CMS,
half of CMS-V were injected with ketamine (CMS-V + KET) (Tornese
et al., 2019), and sucrose preference test was repeated 24 h later
(Fig. 1C). Ketamine completely restored the anhedonic phenotype
(One-Way ANOVA, F(3,43) = 25,83 p < .001).
CMS was found to increase the circulating levels of corticosterone in
CMS-V (no significant increase in CMS-R), while ketamine had no ef-
fects at this level (Fig. 1D; One-Way ANOVA F(3,44) = 14,19,
p < .001). Although a trend towards increasing adrenal glands weight
was observed in stressed animals, no statistically significant changes
were observed (Fig. 1E; One-Way ANOVA F(3,43) = 1,91, p > .05).
3.2. CMS and ketamine had no effect on ionotropic glutamate receptors
mRNA expression or on AMPA subunits RNA editing and splicing levels in
HPC
To assess whether CMS and acute ketamine may affect glutamate
receptors in the HPC, we first measured mRNA expression levels of the
main AMPA and NMDA receptor subunits. No statistically significant
differences were found in any of the analyzed mRNAs (Table 1, One-
Way ANOVA, p > .05).
Moreover, no changes were induced by CMS or KET treatment in the
editing levels at the R/G sites or in the flip/flop RNA splicing ratio of all
AMPA receptor subunits tested (Table 2, One-Way ANOVA, p > .05).
3.3. Modulation of ionotropic glutamate receptor subunits expression and
phosphorylation levels induced by CMS and ketamine in HPC
Western blot analyses for AMPA and NMDA receptor subunits were
performed on total cell homogenate and purified synaptic membranes
from HPC of CNT, CMS-R, CMS-V and CMS-V + KET, to assess changes
in protein expression/phosphorylation.
Considering AMPA receptors, in total homogenate, no significant
alterations were measured among experimental groups, despite some
inter-individual variations especially in GluA1 phosphorylation (Fig. 2;
One-Way ANOVA, F(3,18) = 0,95 p > .05). On the other hand, at sy-
naptic level, while no changes were found in GluA1 (Fig. 3A-C; One-
Way ANOVA F(3,26) = 1,12, p > .05), GluA2 total expression and
phosphorylation at Ser880 were significantly modulated by CMS
(Fig. 3D, E). A marked increase of GluA2 levels at synaptic membranes
was measured after CMS exposure, although significance was reached
only for CMS-R group (Fig. 3D; One-Way ANOVA F(3,24) = 5,05,
p < .01). GluA2 phosphorylation at Ser880, known to promote subunit
internalization (Anggono and Huganir, 2012), was instead significantly
increased in HPC synaptic membranes from both CMS-R and CMS-V,
while the levels in CMS-V + KET animals were not different from
controls, suggesting that ketamine may partly dampen the increase of p-
Ser880-GluA2 induced by CMS (Fig. 3E; One-Way ANOVA
F(3,21) = 5,68, p < .01).
CMS remarkably affected NMDA receptor subunits expression le-
vels, both in total homogenate and synaptic membranes (Figs. 4 and 5).
In total extract, GluN1 levels were significantly reduced in all stressed
animals (independently on stress vulnerability and drug treatment)
(Fig. 4A; One-Way ANOVA, F(3,15) = 9,47, p < .001). At the same
time, both GluN2A and GluN2B expression showed a clear trend for
reduction after CMS, although significance was reached only in CMS-R
for GluN2A (Fig. 4B; One-Way ANOVA, F(3,15) = 4,62, p < .05), and in
CMS-V and CMS-V + KET for GluN2B (Fig. 4C; One-Way ANOVA
F(3,18) = 4,86, p < .05). We also measured GluN2A/GluN2B ratio,
which is considered a key factor in regulating glutamate synapses ac-
tivity (Yashiro and Philpot, 2008), and found no significant changes in
total homogenate, despite a trend towards increase in CMS-V + KET
rats (Fig. 4D; One-Way ANOVA F(3,14) = 2,04, p > .05).
A completely different pattern was revealed in HPC synaptic
membranes. Indeed, opposite to what observed in the cell lysate, GluN1
levels were remarkably increased in all stressed animals (Fig. 5A; One-
Way ANOVA F(3,22) = 4,08, p < .05). No significant alterations were
found in GluN2A (Fig. 5B; One-Way ANOVA F(3,25) = 0,29, p > .05)
and GluN2B (Fig. 5C; One-Way ANOVA F(3,25) = 1,80, p > .05), al-
though GluN2B showed an increasing trend in all CMS rats. Conse-
quently, GluN2A/GluN2B ratio was significantly decreased in HPC sy-
naptic membranes of all stressed groups (Fig. 5D; One-Way ANOVA
F(3,18) = 4,68, p < .05).
3.4. Modulation of metabotropic glutamate receptor subunits expression
levels induced by CMS and ketamine in HPC
To assess whether CMS and ketamine were able to modulate mGlu
receptor levels, we measured their expression in HPC total homogenate
and purified synaptic membranes from all the experimental groups. The
analysis was limited to the most expressed and characterized mGlu
receptors: mGlu1, mGlu2 and mGlu5 (Ferraguti and Shigemoto, 2006)
(Fig. 6).
No alterations were measured for mGlu1 and mGlu5, both for total
expression and at synaptic level (Fig. 6A,D for mGlu1 One-Way ANOVA
F(3,49) = 0,68, F(3,29) = 1,03, p > .05; Fig. 6C,F for mGlu5; One-Way
ANOVA F(3,40) = 1,53, F(3,30) = 2,18, p > .05). On the other hand,
mGlu2 expression was significantly reduced in HPC homogenate and
synaptic membranes, selectively in CMS-V rats, while acute ketamine
completely restored this reduction (Fig. 6B: homogenate, One-Way
ANOVA F(3,49) = 3,78, p < .05; Fig. 6E: synaptic membranes, One-
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Way ANOVA F(3,29) = 5,56, p < .01). This was not dependent on
modulation of mRNA expression (log2-ΔΔct: CNT 0.000 ± 0.030, CMS-
R -0.044 ± 0.064, CMS-V 0.036 ± 0.048, CMS-V + KET
0.0855 ± 0.067, N = 10; One-Way ANOVA, p > .05).
4. Discussion
In this study we used the classical CMS model of depression in rats
(Willner, 2017; Tornese et al., 2019) to investigate the modifications
induced by chronic stress and acute ketamine injection on AMPA/
NMDA ionotropic and metabotropic glutamate receptors at the tran-
scriptional, post transcriptional and translational level. In particular,
we assessed their modifications in the HPC of rats phenotypically re-
silient or vulnerable to CMS and in CMS vulnerable animals treated
with antidepressant dose of ketamine (10 mg/kg) 24 h before sacrifice.
The separation of animals in resilient and vulnerable to CMS was
performed using the sucrose preference test (Tornese et al., 2019). To
assess changes in the activation of the hypothalamic-pituitary-adrenal
axis, we measured corticosterone serum levels and adrenal glands
weight, finding, as previously reported, a marked increase in corticos-
terone serum levels in CMS vulnerable rats, which were not modulated
by acute ketamine. However, differently from our previous report
(Tornese et al., 2019), we did not measure any significant change of
corticosterone in CMS resilient animals, nor of adrenal glands weight,
in any of the experimental groups. The lack of significance could be due
to the lower number of animals used here (N= 11–13), compared with
the previous study (N = 21–54).
Although chronic stress and ketamine had no effect on ionotropic
glutamate receptors mRNAs (expression, editing and splicing), we
found selective modulations in their protein expression, phosphoryla-
tion and localization at synaptic membranes in HPC.
Fig. 1. - Sucrose preference test and alterations of the hypothalamic-pituitary-adrenal axis. A- Sucrose preference of CNT and CMS rats, 3 weeks after CMS start. N:
CNT = 12, CMS = 35. Unpaired t-test. B- Separation of resilient (CMS-R) and vulnerable (CMS-V) animals applying a cut-off at 55% of sucrose preference, 3 weeks
after CMS start. N: CNT = 12, CMS-R= 13, CMS-V = 22. One-Way ANOVA, Tukey's post-hoc test. C- Sucrose preference of CNT, CMS-R, CMS-V and CMS-V + KET
rats, 5 weeks after CMS start and 24 h after ketamine injection. N: CNT = 12, CMS-R = 13, CMS-V = 11, CMS-V + KET = 11. One-Way ANOVA, Tukey's post-hoc
test. D- Corticosterone serum levels in CNT, CMS-R, CMS-V and CMS-V + KET rats, 5 weeks after CMS start and 24 h after ketamine injection. N and statistics as in C.
E- Adrenal glands/body weight (mg/g) in CNT, CMS-R, CMS-V and CMS-V+ KET rats, 5 weeks after CMS start and 24 h after ketamine injection. N and statistics as in
C. Data are shown as means + SEM. *** p < .001 vs CNT; §§ p < .01, §§§ p < .001 vs CMS-R; ### p < .001 vs CMS-V.
Table 1
- qPCR analysis of ionotropic glutamate receptor coding mRNAs. Expression levels of GRIA1, GRIA2, GRIA3, GRIA4 and GRIN1, GRIN2A, GRIN2B mRNA by qPCR.
Data are reported as log2-ΔΔct (expression level of control sample is equal to 0) and as means± SEM (N = 8–10). One-Way ANOVA p > .05.
CNT CMS-R CMS-V CMS-V + KET ANOVA
GRIA1 0.002 ± 0.102 −0.031 ± 0.059 −0.171 ± 0.097 −0.125 ± 0.096 F(3,32) = 1,03
GRIA2 0.001 ± 0.786 −0.058 ± 0.096 −0.074 ± 0.205 0.037 ± 0.088 F(3,30) = 3,79
GRIA3 0.000 ± 0.080 −0.128 ± 0.106 −0.287 ± 0.128 −0.134 ± 0.095 F(3,32) = 0,76
GRIA4 0.002 ± 0.041 −0.180 ± 0.064 −0.246 ± 0.110 −0.150 ± 0.101 F(3,32) = 1,35
GRIN1 0.001 ± 0.500 −0.082 ± 0.056 −0.187 ± 0.070 −0.181 ± 0.156 F(3,34) = 0,81
GRIN2A 0.001 ± 0.110 0.036 ± 0.185 −0.284 ± 0.202 −0.143 ± 0.104 F(3,32) = 1,61
GRIN2B 0.000 ± 0.079 −0.102 ± 0.079 −0.210 ± 0.111 −0.164 ± 0.114 F(3,36) = 1,91
M.E.A. Elhussiny, et al. Progress in Neuropsychopharmacology & Biological Psychiatry 104 (2021) 110033
5
4.1. AMPA receptors
Considering AMPA receptors, we focused on GluA1 and GluA2
subunits, the most highly expressed in the HPC of the adult brain
(Anggono and Huganir, 2012), and on their phosphorylation state,
modulating receptor activity and localization. In particular, we mea-
sured phosphorylation of GluA1 at Ser831 and Ser845, respectively
known for enhancing channel conductance, and for increasing opening
probability and pick amplitude of AMPA receptor currents, and phos-
phorylation of GluA2 at Ser880, which promotes AMPA receptor inter-
nalization (Lu and Roche, 2012; Wang et al., 2014).
We found no changes in GluA1 expression and phosphorylation ei-
ther in the total extract, or at synaptic membranes. On the other hand,
although GluA2 levels did not show any alterations in HPC homo-
genate, GluA2 synaptic expression was significantly increased only in
CMS resilient rats (although a trend was found also in vulnerable
animals), while its phosphorylation at Ser880 was found augmented
both in CMS resilient and vulnerable rats. Interestingly, considering
that GluA2 phosphorylation at Ser880 in CMS vulnerable rats treated
with ketamine was not different from controls, this may suggest that the
drug attenuated the increase of phosphorylation induced by stress.
Since the constitutive editing of the GluA2 subunit makes AMPA
channels impermeable to Ca2+, and leads to a relatively low con-
ductance compared to GluA1-containing receptors, an increase of
GluA2 at synaptic membrane suggests a stress-induced reduction of
AMPA-mediated synaptic currents (Filippini et al., 2017). However, the
concomitant increase of GluA2 phosphorylation at Ser880 in both re-
silient and vulnerable animals suggests a possible cellular response at-
tempting at increasing the internalization of GluA2-containing AMPA
receptors. On the other hand, the lack of changes in GluA2 synaptic
levels and phosphorylation in the HPC of vulnerable animals treated
with ketamine, compared to controls, suggests a possible stabilization
Table 2
RNA editing and splicing analysis of AMPA receptor coding mRNAs. RNA editing (a) and RNA splicing levels (b) of AMPA receptor coding RNA in CNT, CMS-R, CMS-
V, CMS-V+KET rats. Data are expressed as percentage and as means± SEM (N=5). One-Way ANOVA p > .05.
CNT CMS-R CMS-V CMS-V+KET ANOVA
a. RNA editing
GRIA2 R/G 48.9±1.6 50.1± 0.9 45.9± 1.1 49.6± 0.6 F(3,16) = 0,06
GRIA2 Q/R 100±0.0 100±0.0 100±0.0 100±0.0 F(3,16) = 0,00
GRIA3 R/G 88.5±0.6 89.2± 0.6 89.5± 1.0 90.6± 1.6 F(3,16) = 0,55
GRIA4 R/G 53.4±1.6 54.3± 1.0 53.0± 0.7 53.1± 1.5 F(3,16) = 0,87
b. RNA splicing
GRIA2 flip/flop 44.3±0.7 44.5± 1.1 43.1± 1.2 46.6± 1.2 F(3,16) = 1,47
GRIA3 flip/flop 69.9±0.7 69.4± 1.4 69.8± 0.4 71.2± 0.8 F(3,16) = 0,80
GRIA4 flip/flop 37.9±1.5 40.0± 1.0 40.9± 2.4 42.1± 1.1 F(3,16) = 0,33
Fig. 2. – Protein expression levels and phosphorylation of AMPA receptor subunits in homogenate from HPC. A- Total GluA1, B- GluA1 phospho-Ser831, C- GluA1
phospho-Ser845, D- Total GluA2, E- GluA2 phospho-Ser880, in HPC total homogenate from CNT, CMS-R, CMS-V and CMS-V + KET rats. Data are expressed as
percentage of controls, and shown as means + SEM. N = 8–10.
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Fig. 3. – Protein expression levels and phosphorylation of AMPA receptor subunits in synaptic membranes from HPC. A- Total GluA1, B- GluA1 phospho-Ser831, C-
GluA1 phospho-Ser845, D- Total GluA2, E- GluA2 phospho-Ser880, in HPC synaptic membranes from CNT, CMS-R, CMS-V and CMS-V + KET rats. Data are expressed
as percentage of controls and shown as means + SEM. N = 8–10; Tukey's post-hoc test* p < .05, ** p < .01 vs CNT.
Fig. 4. – Protein expression levels of NMDA receptor
subunits in homogenate from HPC. A- Total GluN1,
B- Total GluN2A, C- Total GluN2B, D- GluN2A/
GluN2B ratio, in HPC total homogenate from CNT,
CMS-R, CMS-V and CMS-V + KET rats. Data are
expressed as percentage of controls and shown as
means + SEM. N = 8–10;. Tukey's post-hoc test *
p < .05, ** p < .01 vs CNT.
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Fig. 5. – Protein expression levels of NMDA receptor
subunits in synaptic membranes from HPC. A- Total
GluN1, B- Total GluN2A, C- Total GluN2B, D-
GluN2A/GluN2B ratio, in HPC synaptic membranes
from CNT, CMS-R, CMS-V and CMS-V + KET rats.
Data are expressed as percentage of controls and
shown as means + SEM. N = 8–10; Tukey's post-hoc
test * p < .05, ** p < .01 vs CNT.
Fig. 6. – Protein expression levels of mGlu receptor subunits in homogenate and synaptic membranes from HPC. A- Total mGlu1, B- Total mGlu2, C- Total mGlu5, in
HPC total homogenate from CNT, CMS-R, CMS-V and CMS-V + KET rats. D- Total mGlu1, E- Total mGlu2, F- Total mGlu5, in HPC synaptic membranes from CNT,
CMS-R, CMS-V and CMS-V + KET rats. Data are expressed as percentage of controls and shown as means + SEM. N = 8–10; Tukey's post-hoc test * p < .05 vs CNT;
§ p < .05 vs CMS-R; # p < .05 vs CMS-V.
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of AMPA receptor functional properties induced by the drug.
A previous study reported increased protein expression of total
GluA2 in the HPC after five weeks of chronic unpredictable mild stress
(Li et al., 2011). Although partly in contrast with our results, showing
changes only at synaptic compartment, both works sugget an involve-
ment of GluA2 in the cellular response to chronic stress.
4.2. NMDA receptors
We also found modifications in NMDA receptor subunits total ex-
pression levels and synaptic membrane localization, induced in the HPC
by CMS and ketamine treatment.
NMDA receptors are tetramers composed of two constitutive GluN1
subunits, forming the channel pore, and mainly GluN2A or GluN2B
subunits; the precise combination of subunits determines the functional
properties of the receptor (Sanz-Clemente et al., 2013). It is well known
that NMDA receptor subunit composition changes during development:
while GluN2B is abundant in the early postnatal brain, the level of
GluN2A, characterized by faster rising and decay kinetics, increases
progressively during development (Lohmann and Kessels, 2014). In the
adult brain, GluN2A is enriched at synaptic sites, while GluN2B is
mainly extrasynaptic (Bellone and Nicoll, 2007), and the GluN2A/
GluN2B ratio was shown to be regulated in response to changes of
neuronal activity (Yashiro and Philpot, 2008). In particular, it was
demonstrated that increased GluN2A/GluN2B ratio is related with in-
creased synaptic stimulation and transmission, and that its dynamic
regulation is a major determinant of synaptic plasticity (Malenka and
Bear, 2004).
In HPC total extract, a marked reduction of the expression levels of
GluN1 in all stressed animals was observed, that was not reversed by
ketamine treatment. A similar reduction was also measured in GluN2A
and GluN2B subunits expression, although significance was respectively
reached only in resilient and in vulnerable rats (independently on ke-
tamine treatment). No significant changes were instead observed for
GluN2A/2B ratio, although high variability was noticed in vulnerable
animals treated with ketamine, suggesting individual molecular dif-
ferences in drug response at this level. Unfortunately, the available
number of animals did not allow possible correlation with the beha-
vioral antidepressant response.
Intriguingly, a completely different pattern was found in the sy-
naptic membrane fraction. Here, a remarkable increase of GluN1 levels
was measured in all stressed rats (independently on stress vulnerability
or drug treatment), together with no changes in GluN2A and a trend
towards increase for GluN2B levels. Consequently, GluN2A/2B ratio
was markedly reduced in synaptic membranes of stressed rats.
Altogether, these data suggest that, after chronic stress exposure, in
the face of a general reduction of NMDA receptors cellular levels, as
indirectly indicated by the downregulation of the constitutively ex-
pressed GluN1 subunit, NMDA receptors with decreased GluN2A/2B
ratio are enriched at synaptic membranes. This is suggestive of possible
defects of synaptic activity and plasticity in stressed animals, which are
not dampened in resilient rats or in by ketamine treated vulnerable rats.
In line with the hypothesis of altered synaptic function induced by
chronic stress, previous studies consistently reported decreased Long-
Term Potentiation (LTP) and Excitatory Post-Synaptic Currents (EPSCs)
in the HPC of chronically stressed animals (Joels et al., 2012; Marsden,
2013).
Changes in AMPA and NMDA receptor subunits after chronic stress
exposure were already evaluated in previous studies, although con-
flicting results were obtained depending on the stress protocol, the
species, the strain, and/or the brain area considered. First, one study
reported that chronic unpredictable stress induced a selective down-
regulation of AMPA receptors (and not NMDA receptors) in the HPC,
while a loss of surface AMPA and NMDA receptor subunits was found in
the prefrontal cortex (Kallarackal et al., 2013). Second, another study
found that the expression of the obligatory GluN1, as well as of the
accessory GluN2A and GluN2B subunits, increased in the ventral HPC
of adult rats after CMS exposure for six weeks, at both mRNA and
protein levels (Calabrese et al., 2012). Third, a recent study did not
reveal any modification of GluN1 in the HPC, but increased expression
in the prefrontal cortex from rats subjected to CMS for seven weeks
(Pochwat et al., 2014).
4.3. mGlu2 receptors
mGlu2 is a presynaptic metabotropic glutamate receptor, whose
activation negatively modulates glutamate release (Chaki et al., 2013);
recent evidence has associated changes in mGlu2 levels with stress
vulnerability (Nasca et al., 2015; Highland et al., 2019).
We observed that, both in HPC total extract and synaptic mem-
branes, CMS selectively induced a decrease of mGlu2 in vulnerable rats,
with no alterations in resilient animals. The present findings are in line
with a previous study reporting that mice exposed to chronic stress
showed decreased expression of mGlu2 in HPC and prefrontal cortex;
however, while in the prefrontal cortex the reduction was significant in
all stressed animals, in the HPC the reduction of mGlu2 was selectively
found in vulnerable mice (Nasca et al., 2015).
The receptor has also gained attention as putative target for the
development of novel antidepressants, with both agonists and antago-
nists under study (Chaki et al., 2013; Bruno et al., 2017; Lundstrom
et al., 2017; O'Brien et al., 2018).
In the present work, we found for the first time that acute anti-
depressant treatment with ketamine was able to completely rescue the
reduction of mGlu2 levels induced in the HPC of vulnerable animals by
chronic stress. Although the functional outcomes of these changes on
glutamate neurotransmission remain elusive, our results further support
the involvement of mGlu2 in stress susceptibility and antidepressant
response. In line with this hypothesis, a recent paper demonstrated that
acute treatment with the mGlu2 positive allosteric modulator
LY487379 rescued the depressive-like phenotype, as well as electro-
physiological alterations, induced in the HPC of mice subjected to
chronic restraint stress (Mango et al., 2019).
4.4. Limitation of the study
First, only male rats were included in the experimental protocol,
despite the markedly higher prevalence of major depression among
women compared to men (Kuehner, 2017). A large number of clinical
and preclinical evidence documented sex differences in brain anatomy,
chemistry, and function, as well as in stress and drug responses
(Bangasser and Valentino, 2014; Labonté et al., 2017; Sarkar and
Kabbaj, 2016; Herzog et al., 2020). Previous studies showed both be-
havioral and neurobiological sex differences in the CMS model of de-
pression (reviewed in Franceschelli et al., 2014), as well as in ketamine
response (Strong and Kabbaj, 2018; Ardalan et al., 2020). In the present
explorative study it was chosen to use male rats only. Further work is
warranted to analyse sex differences in the CMS model.
Second, we analyzed the whole hippocampus without differ-
entiating between dorsal and ventral sub-regions. It is believed that the
dorsal hippocampus, interfacing with cortical regions involved in in-
formation processing, performs primarily cognitive functions, while the
ventral hippocampus, projecting to other structures of the limbic system
(i.e. amygdala, nucleus accumbens and hypothalamus), is involved
primarily in emotional behavior and motivation (Fanselow and Dong,
2010; Lee et al., 2017).
In the present explorative study, we decided to use the whole hip-
pocampus, without dividing in dorsal and ventral, to find general
modifications in glutamate receptors expression and regulation in the
area.
Finally, we decided to treat with ketamine only animals vulnerable
to CMS and not naïve and resilient ones. Indeed, it is important to
notice that previous work reported that subanesthetic ketamine has no
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effect on sucrose intake in naïve animals (Autry et al., 2011). Moreover,
in a separate set of animals, we found no effect of ketamine in the su-
crose preference test in CMS-R rats (Tornese et al., 2019). Taken to-
gether, these results show that ketamine affects hedonic behavior only
in animals subjected to chronic stress.
5. Conclusion
In the present study, we found that CMS induces in HPC alterations
of ionotropic glutamate receptors expression, phosphorylation and lo-
calization at synaptic membranes, which are generally independent on
stress vulnerability/resilience and not affected by antidepressant keta-
mine treatment. Interestingly, main alterations were found at synaptic
level, where an enrichment of GluA2-containing AMPA receptors and
NR2B-containing NMDA receptors was measured in stressed animals.
These results are in line with a hypofunction of activity-dependent
glutamatergic synaptic transmission induced by chronic stress ex-
posure, as previously reported by other authors in several animal
models of depression (as a recent review, see (Duman et al., 2019).
On the other hand, a completely different role in the response to
stress and ketamine treatment seems to be played by metabotropic
glutamate receptors, especially the mGlu2 subunit. Indeed, mGlu2 un-
dergoes a selective downregulation in vulnerable animals, which is
completely restored by acute ketamine treatment. This suggests a pos-
sible functional role of mGlu2 in regulating stress vulnerability and fast
antidepressant response, as previously hypothesized (Nasca et al., 2015;
Nasca et al., 2017), but never shown before for acute ketamine treat-
ment.
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